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Background: Recently it has been revealed that lung adenocarcinomas with distinct gene mutations or fusions are
associated with particular histopathological entities. For example, epidermal growth factor receptor (EGFR) gene
mutations are often associated with well differentiated adenocarcinoma of the lung with bronchioloalveolar pattern.
On the other hand, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion
gene in a subset of lung adenocarcinoma is related to mucinous cribriform histology.
Case presentation: Reported herein is a case of synchronous EML4-ALK positive lung adenocarcinoma and
adenocarcinoma in situ in the bilateral lungs of a 55-year-old Japanese woman. The woman had EML4-ALK positive
lung adenocarcinoma in the right lower lung while adenocarcinoma in situ in the left upper lung, which was
EML4-ALK negative.
Conclusion: To our knowledge, this is the first report of synchronous, bilateral lung adenocarcinomas composed
of EML4-ALK positive and negative ones.
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Adenocarcinomas of the lung comprise a group of diseases
with heterogeneous clinicopathological characteristics
[1,2]. Histopathologically, adenocarcinoma of the lung is
composed of a subtype or mixture of subtypes, including
adenocarcinoma in situ (the former bronchioloalveolar),
papillary, or acinar ones [1,2].
Recent advances in molecular genomic analyses of
lung adenocarcinoma specimens have revealed recurrent
association of distinct gene mutations or fusions with
particular clinicopathological entities [3]. For example,
constitutively active mutations of epidermal growth fac-
tor receptor (EGFR) gene are often associated with well
differentiated adenocarcinoma of the lung showing* Correspondence: hiros@hyo-med.ac.jp
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reproduction in any medium, provided the orbronchioloalveolar pattern. Furthermore, using a func-
tional cloning approach with foci-forming assay, Soda
et al. [4] discovered echinoderm microtubule-associated
protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK)
fusion gene in a subset of lung adenocarcinoma. EML4-
ALK positive lung adenocarcinoma typically occurs in
young subjects with non- or low smoking habits [5,6].
Histologically, mucinous cribriform pattern is shown to be
frequently associated with EML4-ALK positive lung
adenocarcinoma [5-7].
Following this breakthrough, a number of kinase gene
fusions have been identified in subsets of adenocarcinoma
of the lung, the examples of which include RET or ROS1
fusions [7-9]. Most of these fusion genes contained genes
for tyrosine kinases as a fusion partner, which are associ-
ated with constitutive (ligand-independent) activities.
Since the activities of these fused kinases and mutated
kinases are shown to be tumorigenic in cell culturel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Preoperative chest CT image. It reveals a 38×12 mm
stellate-shaped mass in the right lower lobe (a) and a 15×10 mm
ground-glass opacity shadow in the left upper lobe of the lung (b).
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ising candidates for therapeutic targets. In fact, small mol-
ecule tyrosine kinase inhibitors have shown dramatic
therapeutic effects on subsets of lung adenocarcinoma,
once oncogenic tyrosine kinases of the cancers are identi-
fied. Examples include gefitinib for EGFR mutation-positive
lung adenocarcinoma and crizotinib for EML4-ALK posi-
tive lung adenocarcinoma.
With regard to these advances in molecular phenotyping,
identification of particular histopathological subtypes of
lung adenocarcinomas, including bronchioloalveolar pat-
tern or mucinous cribriform pattern, will give important
clues for therapeutically tractable genomic changes, such
as EGFR gene mutations or EML4-ALK fusion gene.
Reported herein is a case of synchronous EML4-ALK
positive lung adenocarcinoma and adenocarcinoma in situ
in the bilateral lungs of a 55-year-old Japanese woman.
The woman had EML4-ALK positive lung adenocarcin-
oma in the right lower lung while adenocarcinoma in situ
in the left upper lung.
Case presentation
A 55-year-old Japanese woman was referred to Yodogawa
Christian Hospital because of incidental finding of an
abnormal shadow in the chest X-ray. She was a never-
smoker. Chest computerized tomography (CT) examin-
ation revealed a 38×12 mm-sized stellate-shaped mass
in the right lower lobe (Figure 1a) and a 15×10 mm
ground-glass opacity shadow in the left upper lobe of
the lung (Figure 1b). Apparently no enlargement of
mediastinal lymph nodes were detected on the CT.
Endoscopic biopsy of the left lung tumor showed adeno-
carcinoma (data not shown). Right lower lobectomy and
left upper segmentectomy were performed to resect
both mass. Cut surface of the resected tumors revealed
a gray stellate-shaped mass in the right lung and a white
and yellowish mass with relatively clear border in the
left lung (data not shown).
The tissue was fixed in 10% buffered formalin and em-
bedded in paraffin. Three-micrometer-thick sections were
stained with hematoxylin and eosin (HE). Immunohisto-
chemistry was performed on representative sections with
appropriate antigen retrieval. A primary antibody against
ALK was purchased from NICHIREI (NICHIREI 413681;
clone #5A4) and the immunostained signal was visualized
using I-VIEW DAB universal kit (Roche diagnostics,
Switzerland). For mutational analysis, genomic DNA was
extracted from formalin-fixed, paraffin-embedded tissue
sections using Genomic DNA Extraction Kit (Qiagen,
Hilden, Germany). DNA sequencing for EGFR gene muta-
tion was performed as described [10] with minor modifi-
cations. Fluorescent in situ hybridization (FISH) analysis
using probes for EML4 and ALK genes was performed as
described previously [7].Microscopic examination of the resected right lower
lobe revealed a heterogenous adenocarcinoma composed
of a mucinous cribriform tumor (Figure 2a) and lepidic
growth (adenocarcinoma in situ) pattern (Figure 2c). At
low-power microscopy, these two components were seen
adjacent to each other (data not shown). As described
above, the mucinous cribriform histology of the HE
stained specimen made us suspicious of EML4-ALK posi-
tive lung adenocarcinoma [5-7]. To examine this possibil-
ity, immunohistochemical analysis was performed. At
low-power microscopy, the tumor was homogeneously
stained positive for ALK (data not shown). At high-power
microscopy, the tumor cells were positively stained for
ALK (Figures 2b,d). Fusion and split FISH analyses using
probes for EML4 and ALK genes confirmed that the
adenocarcinoma of the right lung was indeed EML4-ALK
positive (Figures 2g-j). We confirmed that the EML4-ALK
positive adenocarcinoma has no mutations in exons 18,
19, 20, 21 of EGFR gene (data not shown).
On the other hand, the resected left upper lobe speci-
men contained a adenocarcinoma in situ (Figure 2e).
Figure 2 Histological and FISH analysis. Microscopic and immunohistochemical examination of the right lung cancer reveals a mucinous
cribriform pattern (a) (HE stain, ×200), which is positive for ALK (b) (immunohistochemical staining, ×200). The right lung cancer also contains a
bronchioloalveolar pattern (c) (HE stain, ×200), which is again positive for ALK (d) (immunohistochemical staining, ×200). On the other hand, the
left lung cancer is composed singly of a bronchioloalveolar pattern (e) (HE stain, ×200), which is negative for ALK (f) (immunohistochemical
staining, ×200). FISH analyses revealed EML4-ALK fusion gene in the tumor of the right lung (g-j). FISH signals in a single tumor cell are shown.
(g)-(i) EML4-ALK fusion FISH. The signals for ALK gene (g) and EML4 gene (h) are indicated by green and red dots, respectively. The signal for
EML4-ALK fusion gene is indicated by a white arrow (i). (j) ALK split FISH. The signals for 5′ and 3′ probe for ALK gene are indicated by green and
red dots, respectively. Split of the green and the red dots is consistent with the presence of EML4-ALK fusion gene.
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searched for EGFR mutations for exons 18, 19, 20, and
21 in the genomic DNA from the adenocarcinoma in
situ, but none of them were found (data not shown).
As an adjuvant therapy, the patient has taken orally
tegafur-uracil 300 mg/day since 3 months after the re-
section operation. Until now, she has not shown any
signs of relapse or adverse effects. Eleven months after
the operation, neither chest CT, nor bone scintigraphy,
nor brain magnetic resonance imaging did show any
signs of relapse or metastasis.
Conclusion
In this report, we described a case of synchronous bilat-
eral lung cancers with EML4-ALK positive adenocarcin-
oma in the right lung and adenocarcinoma in situ in the
left, which was EML4-ALK negative. To our knowledge,
this is the first report of a case of synchronous lung
adenocarcinomas of this combination.
A number of cases of synchronous multiple lung adeno-
carcinomas were reported previously. The most frequent
components in those cases were well differentiated adeno-
carcinoma with mixed bronchioloalveolar pattern [11].
Graziano et al. [12] reported a case of synchronous bilateral
adenocarcinoma in situ of the lung with distinct mutations
of EGFR gene. Some of these cases were associated with
atypical adenomatous hyperplasia [13,14]. Adenocarcinoma
in situ of the lung was frequently associated with EGFRgene mutation [15,16]. There is a case of multiple adeno-
carcinomas in situ of the lung having the same mutation of
EGFR in common [17].
In our case, although the bilateral adenocarcinomas
have bronchioloalveolar pattern in common, the right lung
cancer was EML4-ALK positive while the left one was not.
Furthermore, EGFR gene mutations were not detected in
the exons 18 to 21 in “pure” bronchioloalveolar adenocar-
cinoma in the left lung. Over 90% of EGFR mutations
were reported to be localized in these 4 exons [18]. Thus,
it is unlikely that the adenocarcinoma in situ in the left
lung has EGFR mutation. Interestingly, Togashi et al. re-
cently identified KLC1-ALK fusion gene in a case of
adenocarcinoma in situ of the lung [19]. However, in our
case, the adenocarcinoma in situ of the left lung was
immunohistochemically negative for ALK. Therefore, it is
unlikely that the left lung cancer is ALK fusion-positive.
The right tumor and the left one had lepidic growth pat-
tern in common, although the former was EML4-ALK
positive, while the latter negative. The relationship be-
tween genetic alterations and histology is intriguing and it
will be interesting to compare gene expression profiling of
both tumors.
The fact that the tumor of the right lung and that of the
left lung harbor different genetic alterations will be useful
for the follow-up of this patient. The adenocarcinoma in
situ of the left lung was 15×10 mm of size and pathologic-
ally at stage 0 (TisN0M0). Therefore, the possibility of
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as nearly 0%. On the other hand, the EML4-ALK-positive
tumor of the right lung was an invasive cancer. Thus, if
any metastasis or relapse occurs in the future in this
patient, it is more likely that the relapse derives from
EML4-ALK-positive cancer of the right lung. After the
confirmation that the metastasis or relapse harbor EML4-
ALK translocation, ALK inhibitor such as crizotinib will be
the first choice. EML4-ALK fusion gene occurred around
3% of “non-smoker” adenocarcinomas of the lung [7]. In
addition to the EML4-ALK fusion, not only other fusion
partner for ALK gene, but also novel kinase gene fusions
have been discovered in a subset of lung adenocarcinoma
[7-9]. It was reported that these kinase gene fusion-positive
lung adenocarcinomas have some histological correlates or
surrogates including mucinous cribriform pattern [7].
However, as our case report illustrated, kinase gene fusion-
positive lung adenocarcinomas may show different hist-
ology other than mucinous cribriform pattern. Not only
tumor histology, but also patients’ sex, age, smoking habit,
and so on, should be considered to suspect the involve-
ment of kinase gene fusion in lung cancers. Although rarer
than lung cancer with EGFR mutation, the identification of
kinase gene fusions, including EML4-ALK, in lung cancer
leads to molecularly-targeted therapy with kinase inhibi-
tors. The identification has important implication for tract-
able therapy and predictable prognosis.
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